Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pharming Group N.V. (PHAR)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
10.30-0.13 (-1.25%)
At close: 03:40PM EDT
10.80 +0.78 (+7.78%)
After hours: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference

    Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.

  • PR Newswire

    Pharming Group reports financial results for the first half of 2022

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022.

  • PR Newswire

    Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

    Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that a new diagnosis code for reporting cases of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be added to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) by the US Centers for Disease Control and Prevention (CDC). The diagnosis code, D81.82 ‒ Activated Phosphoinositide 3-kinase Delta Syndrome (APDS)

Advertisement
Advertisement